Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 219

1.

Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery.

Ataseven B, du Bois A, Reinthaller A, Traut A, Heitz F, Aust S, Prader S, Polterauer S, Harter P, Grimm C.

Gynecol Oncol. 2015 Jul 8. pii: S0090-8258(15)30067-6. doi: 10.1016/j.ygyno.2015.07.005. [Epub ahead of print]

PMID:
26163893
2.

AGO Austria recommendations for genetic testing of patients with ovarian cancer.

Marth C, Hubalek M, Petru E, Polterauer S, Reinthaller A, Schauer C, Scholl-Firon T, Singer CF, Zschocke J, Zeimet AG.

Wien Klin Wochenschr. 2015 Jun 25. [Epub ahead of print]

PMID:
26109557
3.

Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.

Volgger B, Zeimet AG, Reinthaller A, Petru E, Schauer C, Klein M, Sevelda-Schwarzgruber U, Bogner G, Wolfram G, Marth C.

Int J Gynecol Cancer. 2015 Feb;25(2):257-62. doi: 10.1097/IGC.0000000000000352.

PMID:
25611899
4.

Plasma fibrinogen levels in patients with benign and malignant ovarian tumors.

Hefler-Frischmuth K, Lafleur J, Hefler L, Polterauer S, Seebacher V, Reinthaller A, Grimm C.

Gynecol Oncol. 2015 Mar;136(3):567-70. doi: 10.1016/j.ygyno.2014.12.041. Epub 2015 Jan 7.

PMID:
25576886
5.

Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.

Lamm W, Natter C, Schur S, Köstler WJ, Reinthaller A, Krainer M, Grimm C, Horvath R, Amann G, Funovics P, Brodowicz T, Polterauer S.

BMC Cancer. 2014 Dec 18;14:981. doi: 10.1186/1471-2407-14-981.

6.

Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.

Floquet A, Vergote I, Colombo N, Fiane B, Monk BJ, Reinthaller A, Calvert P, Herzog TJ, Meier W, Kim JW, del Campo JM, Friedlander M, Pisano C, Isonishi S, Crescenzo RJ, Barrett C, Wang K, Mitrica I, du Bois A.

Gynecol Oncol. 2015 Jan;136(1):37-42. doi: 10.1016/j.ygyno.2014.11.074. Epub 2014 Nov 28.

PMID:
25434635
7.

Sentinel lymph node detection in vulvar cancer patients: a 20 years analysis.

Brammen L, Staudenherz A, Polterauer S, Dolliner P, Grimm C, Reinthaller A, Sinzinger H.

Hell J Nucl Med. 2014 Sep-Dec;17(3):184-9. doi: 10.1967/s002449910143. Epub 2014 Nov 12.

8.

Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study.

Sehouli J, Reinthaller A, Marth C, Reimer D, Reimer T, Stummvoll W, Angleitner-Boubenizek L, Brandt B, Chekerov R.

Br J Cancer. 2014 Oct 14;111(8):1519-25. doi: 10.1038/bjc.2014.443. Epub 2014 Sep 16.

PMID:
25225907
9.

A collagen-fibrin patch (Tachosil®) for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: a randomized clinical trial.

Grimm C, Polterauer S, Helmy S, Cibula D, Zikan M, Reinthaller A, Tempfer C.

BMC Cancer. 2014 Aug 30;14:635. doi: 10.1186/1471-2407-14-635.

10.

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.

Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E.

J Clin Oncol. 2014 Feb 1;32(4):320-6. doi: 10.1200/JCO.2013.50.5669. Epub 2013 Dec 23.

11.

Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.

Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E, Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R.

Eur J Cancer. 2014 Jan;50(1):99-110. doi: 10.1016/j.ejca.2013.09.011. Epub 2013 Oct 28.

PMID:
24176298
12.

The value of serum albumin as a novel independent marker for prognosis in patients with endometrial cancer.

Seebacher V, Grimm C, Reinthaller A, Heinze G, Tempfer C, Hefler L, Polterauer S.

Eur J Obstet Gynecol Reprod Biol. 2013 Nov;171(1):101-6. doi: 10.1016/j.ejogrb.2013.07.044. Epub 2013 Aug 11.

PMID:
24011381
13.

Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer.

Grimm C, Hofstetter G, Aust S, Mutz-Dehbalaie I, Bruch M, Heinze G, Rahhal-Schupp J, Reinthaller A, Concin N, Polterauer S.

Br J Cancer. 2013 Aug 6;109(3):610-4. doi: 10.1038/bjc.2013.323. Epub 2013 Jul 16.

14.

Association of myeloperoxidase with ovarian cancer.

Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A, Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF.

Tumour Biol. 2014 Jan;35(1):141-8. doi: 10.1007/s13277-013-1017-3. Epub 2013 Jul 27.

15.

L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.

Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M.

J Natl Cancer Inst. 2013 Aug 7;105(15):1142-50. doi: 10.1093/jnci/djt144. Epub 2013 Jun 18. Erratum in: J Natl Cancer Inst. 2013 Nov 20;105(22):1763.

16.

Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trial.

Seebacher V, Hofstetter G, Polterauer S, Reinthaller A, Grimm C, Schwameis R, Taucher S, Wagener A, Marth C, Concin N.

Br J Cancer. 2013 Jul 9;109(1):215-8. doi: 10.1038/bjc.2013.282. Epub 2013 Jun 13.

17.

The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study).

You B, Colomban O, Heywood M, Lee C, Davy M, Reed N, Pignata S, Varsellona N, Emons G, Rehman K, Steffensen KD, Reinthaller A, Pujade-Lauraine E, Oza A.

Gynecol Oncol. 2013 Aug;130(2):289-94. doi: 10.1016/j.ygyno.2013.05.013. Epub 2013 May 18.

PMID:
23694718
18.

Impact of conization type on the resected cone volume: results of a retrospective multi-center study.

Grimm C, Brammen L, Sliutz G, Weigert M, Sevelda P, Pils S, Reinthaller A, Polterauer S.

Arch Gynecol Obstet. 2013 Nov;288(5):1081-6. doi: 10.1007/s00404-013-2873-1. Epub 2013 May 7.

PMID:
23649464
19.

The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer.

Aust S, Horak P, Pils D, Pils S, Grimm C, Horvat R, Tong D, Schmid B, Speiser P, Reinthaller A, Polterauer S.

BMC Cancer. 2013 Mar 14;13:115. doi: 10.1186/1471-2407-13-115.

20.

Expression of Bcl-2 and the antiapoptotic BAG family proteins in ovarian cancer.

Aust S, Pils S, Polterauer S, Horvat R, Cacsire Castillo-Tong D, Pils D, Dudek G, Schmid B, Speiser P, Reinthaller A, Grimm C.

Appl Immunohistochem Mol Morphol. 2013 Dec;21(6):518-24. doi: 10.1097/PAI.0b013e318284a053.

PMID:
23455184
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk